In a significant corporate development, the controlling shareholder of Shenzhen New Industries Biomedical Engineering Co.,Ltd. (SZSE: 300832) has been placed under detention. The company reported first-quarter revenue of 1.129 billion yuan.
Shenzhen New Industries Biomedical Engineering Co.,Ltd. disclosed in a filing that it received notification from the family of its controlling shareholder, Weng Xianding, on July 6. According to a detention notice issued by the relevant supervisory commission, Weng Xianding has been subjected to detention measures.
Background on the Individual
The announcement clarified that Weng Xianding has not held any position within the company since September 8, 2021. The company stated that all directors and senior management are performing their duties normally, and board operations as well as production and management activities remain unaffected. The firm emphasized that this matter does not involve the company and is not expected to have a material impact on its business operations.
Core Business Operations
The company primarily engages in the research and development, production, sales, and customer service of products in the in-vitro diagnostics field. Its core products consist of fully automated chemiluminescence immunoassay analyzers and their matching reagents. The company has established four major technology platforms focusing on nano-magnetic microsphere development, key reagent raw material R&D, fully automated diagnostic instrument development, and diagnostic reagent R&D.
Ownership and Financial Stakes
According to the company's 2025 annual report, Weng Xianding controls approximately 30.05% of the company's shares. As of the announcement date, Tibet New Industries and controlling shareholder Weng Xianding have pledged a cumulative 97.48 million shares. This represents 41.28% of their combined holdings and 12.41% of the company's total share capital. The company noted there is no risk of forced liquidation or share transfer related to these pledges.
Recent Financial Performance
Financially, the company reported operating revenue of 4.577 billion yuan for the full year 2025, marking a slight increase of 0.91% year-over-year. However, its net profit attributable to shareholders declined by 11.39% to 1.62 billion yuan. For the first quarter of 2026, the company generated revenue of 1.129 billion yuan, up 0.34%, with net profit rising 1.02% to 442 million yuan.
Market Reaction to the News
The market reacted negatively to the announcement. By the close of trading on July 6, the company's share price had fallen 7.52% to 40.97 yuan per share. This event follows a trend of increasing market attention on similar cases where executives or controlling shareholders of listed companies have been placed under detention by supervisory authorities this year.
Comments